DE69218241T2 - Arzneistofformulierung zur parenteralen anwendung - Google Patents

Arzneistofformulierung zur parenteralen anwendung

Info

Publication number
DE69218241T2
DE69218241T2 DE69218241T DE69218241T DE69218241T2 DE 69218241 T2 DE69218241 T2 DE 69218241T2 DE 69218241 T DE69218241 T DE 69218241T DE 69218241 T DE69218241 T DE 69218241T DE 69218241 T2 DE69218241 T2 DE 69218241T2
Authority
DE
Germany
Prior art keywords
pct
toremifene
desmethyltamoxifen
tamoxifen
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69218241T
Other languages
English (en)
Other versions
DE69218241D1 (de
Inventor
Harry Goesta Jalonen
Terttu Marita Heikkilae
Hannu Uolevi Jalonen
Lauri Veikko Matti Kangas
Risto Arvo Sakari Lammintausta
Kauko Oiva Antero Kurkela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtyma Oy filed Critical Orion Yhtyma Oy
Application granted granted Critical
Publication of DE69218241D1 publication Critical patent/DE69218241D1/de
Publication of DE69218241T2 publication Critical patent/DE69218241T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
DE69218241T 1991-12-10 1992-12-10 Arzneistofformulierung zur parenteralen anwendung Expired - Fee Related DE69218241T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919126209A GB9126209D0 (en) 1991-12-10 1991-12-10 Drug formulations for parenteral use
PCT/FI1992/000339 WO1993011757A1 (en) 1991-12-10 1992-12-10 Drug formulations for parenteral use

Publications (2)

Publication Number Publication Date
DE69218241D1 DE69218241D1 (de) 1997-04-17
DE69218241T2 true DE69218241T2 (de) 1997-06-19

Family

ID=10706001

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69218241T Expired - Fee Related DE69218241T2 (de) 1991-12-10 1992-12-10 Arzneistofformulierung zur parenteralen anwendung

Country Status (11)

Country Link
US (1) US5571534A (de)
EP (1) EP0616529B1 (de)
JP (1) JP3558344B2 (de)
AT (1) ATE149828T1 (de)
AU (1) AU667861B2 (de)
CA (1) CA2125408C (de)
DE (1) DE69218241T2 (de)
GB (1) GB9126209D0 (de)
NO (1) NO308578B1 (de)
WO (1) WO1993011757A1 (de)
ZA (1) ZA929592B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3545403B2 (ja) * 1993-04-22 2004-07-21 スカイファルマ インコーポレイテッド 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
WO1995015746A1 (en) * 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
GB9411115D0 (en) * 1994-06-03 1994-07-27 Secr Defence Stabilisation of photosensitive material
GB9609171D0 (en) * 1996-05-02 1996-07-03 Orion Yhtymae Oy Antioxidant compounds
DE69804169T2 (de) * 1997-06-27 2002-08-29 Akzo Nobel Nv Oral anzuwendende flüssige Arzneilösung
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
CZ300960B6 (cs) * 1998-05-07 2009-09-23 The University Of Tennessee Research Corporation Lécivo pro lécení prostatické intraepitelové neoplasie
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US6410043B1 (en) 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO2000033917A1 (de) * 1998-12-04 2000-06-15 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten
FI982733A (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
US6303157B1 (en) 2000-05-31 2001-10-16 Kava Pharmaceuticals, Inc. Extracts of kava-kava
US20040029831A1 (en) * 2000-05-31 2004-02-12 Kava Pharmaceuticals, Inc. Extracts of kava-kava
CN1679956A (zh) 2001-11-29 2005-10-12 Gtx公司 治疗因雄激素剥夺引起的症状
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20050239747A1 (en) * 2004-04-21 2005-10-27 Pharmaceutical Industry Technology And Development Center Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods
WO2006001035A2 (en) * 2004-06-28 2006-01-05 Lifecare Innovations Pvt. Ltd. Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof.
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
JP2008514645A (ja) 2004-09-24 2008-05-08 アールエフイー ファーマ エルエルシー 眼疾患およびその他の疾患の局所的処置のためのcaiに基づくシステムおよび方法
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
WO2006066074A2 (en) 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
TW200726485A (en) * 2005-07-01 2007-07-16 Alza Corp Liposomal delivery vehicle for hydrophobic drugs
US20070055200A1 (en) 2005-08-10 2007-03-08 Gilbert Scott J Needle-free jet injection drug delivery device
WO2007078060A1 (en) * 2005-12-30 2007-07-12 Amorepacific Corporation Polymer-liposome nano-complexes and the preparation method thereof, and the composition of skin external application containing the same
RS52737B (en) 2006-10-19 2013-08-30 Genzyme Corporation ROSCOVITINE FOR CERAMIC CYST DISEASES
NZ595212A (en) 2009-03-30 2014-02-28 Eisai R&D Man Co Ltd Liposome composition
WO2010113983A1 (ja) * 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
CN103221052A (zh) 2010-09-16 2013-07-24 施摩达生物技术有限公司 氟维司群组合物及使用方法
WO2013008083A1 (en) 2011-07-13 2013-01-17 National Institute Of Pharmaceutical Education And Research (Niper) Pharmaceutical composition for enhancing anticancer efficacy of tamoxifen
EP2758052B9 (de) 2011-09-18 2019-03-27 Euro-Celtique S.A. HDAC-Hemmer-Cyclopolysaccharidzusammensetzung
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
PT2970346T (pt) 2013-03-15 2018-11-09 Univ California Diésteres de fosfonato nucleosídico acíclico
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
RS63250B1 (sr) 2014-09-15 2022-06-30 Univ California Nukleotidni analozi
CN105748442B (zh) * 2016-04-07 2019-04-12 天津中医药大学 一种红景天苷及他莫昔芬的双载药抗乳腺癌纳米制剂的制备方法
JP7197370B2 (ja) 2016-06-17 2022-12-27 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア がんの予防および/または治療のための化合物、組成物および方法
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
KR20200020899A (ko) * 2017-06-30 2020-02-26 셀진 코포레이션 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법
WO2019118855A1 (en) * 2017-12-14 2019-06-20 The Trustees Of The University Of Pennsylvania Compounds and compositions for prevention and/or treatment of cancer
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5793909A (en) * 1980-12-03 1982-06-11 Sankyo Co Ltd Carcinostatic pharmaceutical having directivity to specific internal organ and its preparation
FR2502951B1 (fr) * 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
FI67538C (fi) * 1982-05-27 1985-04-10 Farmos Oy Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten
DE3331459A1 (de) * 1982-08-31 1984-03-01 Martin Dr.med. 6900 Heidelberg Berger Zubereitung zur tumorbehandlung mit einem gehalt an diazoxid und dessen verwendung
EP0152379A3 (de) * 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
JP2847783B2 (ja) * 1988-08-11 1999-01-20 日清製粉株式会社 抗癌活性増強剤
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
DE3837596A1 (de) * 1988-11-05 1990-05-10 Rosink Gmbh & Co Kg Kannenstock
FR2640137A1 (fr) * 1988-12-08 1990-06-15 Texinfine Sa Systemes transporteurs de principes actifs lipophiles et leur procede d'obtention
EP0528975A4 (en) * 1990-05-17 1993-09-15 Baylor College Of Medicine Growth inhibitors and methods of treating cancer and cell proliferative diseases

Also Published As

Publication number Publication date
ZA929592B (en) 1993-08-06
JP3558344B2 (ja) 2004-08-25
EP0616529B1 (de) 1997-03-12
NO942155D0 (no) 1994-06-09
EP0616529A1 (de) 1994-09-28
WO1993011757A1 (en) 1993-06-24
NO308578B1 (no) 2000-10-02
AU667861B2 (en) 1996-04-18
CA2125408A1 (en) 1993-06-23
ATE149828T1 (de) 1997-03-15
US5571534A (en) 1996-11-05
CA2125408C (en) 2004-04-20
AU3159993A (en) 1993-07-19
JPH07501813A (ja) 1995-02-23
DE69218241D1 (de) 1997-04-17
GB9126209D0 (en) 1992-02-12
NO942155L (de) 1994-06-10

Similar Documents

Publication Publication Date Title
DE69218241T2 (de) Arzneistofformulierung zur parenteralen anwendung
ES2091012T3 (es) Preparacion y utilizacion de nuevos sistemas coloidales dispersables a base de ciclodextrina, en forma de nanoesferas.
ES2115945T3 (es) Preparaciones topicas cosmeticas y medicinales.
BR9406823A (pt) Aminas secundárias e agentes anti-diabéticos e antiobesidade
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
PT790824E (pt) Acidos carboxilicos 2,2-dicloroalcanos medicamentos contendo os mesmos e o seu uso para o tratamento da resistencia a insulina
NO951996L (no) Leveringsinnretning med innkapslede eksipienser
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
ES2090712T3 (es) Medicamento agudo que contiene ibuprofeno y su uso.
DK0945136T3 (da) Topisk lægemiddel indeholdende ciclosporin
EP0327709A3 (de) Platin-Komplex, diesen enthaltendes antineoplastisches Agens, Zwischenprodukt, Verfahren zur Herstellung und Verwendung
DK0615443T3 (da) Lægemiddel i akut virksom form indeholdende Flurbiprofen og anvendelse deraf
DE69808938D1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen
BR9509634A (pt) Solução aquosa concentrada estável ao armazenamento para infusao uso da mesma e processos de preparação da mesma de tratamento de um paciente necessitando de um inibidor de trombina e de estabilização de um inibidor de trombina ativo
JP2001278788A (ja) アラントインを配合した安定な液剤
SE9103110D0 (sv) New drug formulation
KR980002033A (ko) 트리아졸 유도체 또는 그 염
JPS57146723A (en) Pharmaceutical preparation having improved absorption
DE69319589T2 (de) Juckreizstillendes mittel
DE69623641T2 (de) Topisch anzuwendendes abschäumendes arzneimittel zur behandlung von durch pityrosporum ovale verursachten hauterkrankungen
CA2456970A1 (en) Drug formulations for parenteral use
US2611731A (en) Antibiotic preparations
RU95105249A (ru) Гидрохлорид ng монометил-l-аргинина, способы его получения, способ получения фармацевтического препарата и способ лечения
CA2039643C (en) Anti-wart composition
JP2001163777A (ja) 皮膚外用液剤

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ORION CORP., ESPOO, FI

8339 Ceased/non-payment of the annual fee